Cargando…

Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France

INTRODUCTION: The aim of the current study is to estimate the cost-effectiveness of adjuvant treatment with nivolumab relative to clinically relevant comparators in adult patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection from a French soci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bregman, Bruno, Teitsson, Siguroli, Orsini, Isabella, Cotté, François-Emery, Amadi, Adenike, Moshyk, Andriy, Roze, Stéphane, Gaudin, Anne-Françoise
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649185/ https://www.ncbi.nlm.nih.gov/pubmed/32920709 http://dx.doi.org/10.1007/s13555-020-00446-z

Ejemplares similares

Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis
por: Toor, Kabirraaj, et al.
Publicado: (2021)

Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection
por: Batteson, Rachael, et al.
Publicado: (2019)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
por: Samlowski, Wolfram, et al.
Publicado: (2022)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital coSts Assessment)
por: Fernandes, Jérôme, et al.
Publicado: (2017)

Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
por: Baker, Timothy, et al.
Publicado: (2022)

Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia
por: Eriksson, Daniel, et al.
Publicado: (2016)

Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France
por: Cotté, Francois-Emery, et al.
Publicado: (2016)

Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma
por: Federico Paly, Victoria, et al.
Publicado: (2022)

Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study)
por: Assié, Jean-Baptiste, et al.
Publicado: (2020)

Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting
por: Assié, Jean-Baptiste, et al.
Publicado: (2023)

Clinical utility of nivolumab in the treatment of advanced melanoma
por: Asmar, Ramsey, et al.
Publicado: (2016)

Machine Learning–Based Analysis of Treatment Sequences Typology in Advanced Non–Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab
por: Chouaïd, Christos, et al.
Publicado: (2022)

Incidence of venous thromboembolism in France: a retrospective analysis of a national insurance claims database
por: Bouée, Stéphane, et al.
Publicado: (2016)

Nivolumab exposure–response analysis for adjuvant treatment of melanoma supporting a change in posology
por: Sanghavi, Kinjal, et al.
Publicado: (2021)

Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France
por: Cotté, François-Emery, et al.
Publicado: (2011)

Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study)
por: Chouaïd, Christos, et al.
Publicado: (2017)

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
por: Mandalá, Mario, et al.
Publicado: (2021)

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
por: Weber, Jeffrey S., et al.
Publicado: (2023)

Utility of adjuvant systemic therapy in melanoma
por: Eggermont, A. M. M., et al.
Publicado: (2009)

Integrating Quality of Life in the Care Pathway of Cancer Patients Undergoing Immunotherapy Treatment: Descriptive, Cross-sectional Survey of an Online Patient Community's Experiences and Expectations
por: Wilczynski, Ophélie, et al.
Publicado: (2022)

Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2022)

Budget Impact Analysis of Impella CP(®) Utilization in the Management of Cardiogenic Shock in France: A Health Economic Analysis
por: Delmas, Clément, et al.
Publicado: (2022)

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study
por: Barlesi, Fabrice, et al.
Publicado: (2020)

Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study
por: Fauchier, Laurent, et al.
Publicado: (2015)

Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial
por: Branchoux, S., et al.
Publicado: (2021)

A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma(☆)
por: Tarhini, A.A., et al.
Publicado: (2021)

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
por: Khushalani, Nikhil I, et al.
Publicado: (2022)

Management of osteoporosis and associated quality of life in post menopausal women
por: Cortet, Bernard, et al.
Publicado: (2011)

Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment
por: Huas, Dominique, et al.
Publicado: (2010)

Long-term response of vulvar mucosal melanoma treated with neoadjuvant nivolumab
por: Dubus, Margaux, et al.
Publicado: (2023)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts
por: Chouaid, Christos, et al.
Publicado: (2022)

Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2023)

Nivolumab in the treatment of malignant melanoma: review of the literature
por: Mashima, Emi, et al.
Publicado: (2015)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Bicytopenia in Primary Lung Melanoma Treated with Nivolumab
por: Takahashi, Ayumu, et al.
Publicado: (2018)

The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
por: Albrecht, Lea Jessica, et al.
Publicado: (2023)

Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma
por: Bottlaender, Lea, et al.
Publicado: (2017)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i8hk34f9sjrsu70h89iesbd8mq